Markets:

Overview

News

Currencies

International

Treasuries

ADMA Biologics Inc - Common Stock (NQ:ADMA)

9.050 -0.100 (-1.09%)

Streaming Delayed Price Updated: 11:01 AM EDT, Mar 31, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about ADMA Biologics Inc - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

The Great Rotation of 2026: Why Small Caps are Finally Dethroning the Tech Giants

March 27, 2026

The financial landscape of 2026 has been defined by a seismic shift in capital allocation that few analysts predicted with such intensity. For the first time in over a decade, the long-dormant Russell...

Via MarketMinute

What's going on in today's pre-market session ↗

March 27, 2026

Via Chartmill

Why Are Shares Of ADMA Biologics Falling Today? ↗

March 26, 2026

ADMA Biologics, Inc. (NASDAQ: ADMA) shares are tumbling on Thursday as traders lean into risk-off positioning and punish weaker charts in a down tape. The Nasdaq is down 0.91% while the S&P 500 has...

Via Benzinga

Topics Stocks

ADMA Biologics Inc (NASDAQ:ADMA) Reports Record 2025 Results Driven by ASCENIV, Provides 2026 Outlook ↗

February 25, 2026

Via Chartmill

Earnings Scheduled For November 5, 2025 ↗

November 05, 2025

Via Benzinga

Earnings Scheduled For August 6, 2025 ↗

August 06, 2025

Via Benzinga

Is ADMA Biologics Gaining or Losing Market Support? ↗

August 01, 2025

Via Benzinga

Structure Therapeutics Slides 28% This Year as $6 Million Stake Emerges ↗

March 22, 2026

Structure Therapeutics advances oral therapies for diabetes, obesity, and pulmonary disease through its clinical-stage drug pipeline.

Via The Motley Fool

ADMA Biologics (ADMA) Q4 2025 Earnings Transcript ↗

February 28, 2026

ADMA Biologics (ADMA) Q4 2025 Earnings Transcript

Via The Motley Fool

Chime Is Down 27% From Its IPO Price, Yet Posting 29% Revenue Growth: Why This New $15 Million Bet Stands Out ↗

February 14, 2026

This digital banking platform targets U.S. mass market consumers with mobile-first, fee-free services and strategic bank partnerships.

Via The Motley Fool

Topics Initial Public Offering Regulatory Compliance

Is ADMA Biologics Gaining or Losing Market Support? ↗

July 02, 2025

Via Benzinga

How Is The Market Feeling About ADMA Biologics? ↗

June 04, 2025

Via Benzinga

Earnings Scheduled For May 7, 2025 ↗

May 07, 2025

Via Benzinga

Solaris Stock Is Up 100% This Past Year, and One Fund Is Betting $29 Million on More Growth ↗

February 14, 2026

Solaris Energy Infrastructure delivers automation and logistics solutions to U.S. oil and gas operators using proprietary technologies.

Via The Motley Fool

Topics Energy

Stock Up 40% in a Year, $706 Million in Quarterly Sales: Why Boot Barn’s Trimmed Stake Deserves a Look ↗

February 14, 2026

Boot Barn Holdings operates over 500 stores nationwide, supplying western and workwear apparel to a diverse U.S. customer base.

Via The Motley Fool

Topics Regulatory Compliance

This Biotech Is Up 194% in a Year but One Investor Took Millions Off the Table ↗

December 28, 2025

When a biotech rallies nearly 200% and still gets trimmed, the real story likely isn’t about fear or a loss of conviction.

Via The Motley Fool

Topics Regulatory Compliance

ANI Stock Is Up 49% This Past Year, Revenue Is Surging, and One Fund Still Walked Away ↗

December 28, 2025

ANI is firing on all cylinders operationally, which makes this exit less about fundamentals and more about portfolio discipline at a moment when expectations might be sky-high.

Via The Motley Fool

Topics Regulatory Compliance

ADMA Biologics Inc (NASDAQ:ADMA) Emerges as a Top GARP Investment Candidate ↗

December 05, 2025

ADMA Biologics exemplifies GARP investing with strong revenue & earnings growth, high profitability, and a reasonable valuation relative to its biotech peers.

Via Chartmill

This Small-Cap Fund Just Dumped $7 Million in ADMA Stock — Here’s Why ↗

November 01, 2025

This Small-Cap Fund Just Dumped $7 Million in ADMA Stock — Here’s Why

Via The Motley Fool

Redwire Posts Downbeat Q2 Results, Joins Tandem Diabetes Care, Fortinet, Symbotic And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗

August 07, 2025

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

August 07, 2025

Via Benzinga

Why Groupon Shares Are Trading Higher By Around 28%; Here Are 20 Stocks Moving Premarket ↗

August 07, 2025

Via Benzinga

Adma Biologics (ADMA) Q2 Revenue Up 14% ↗

August 06, 2025

Via The Motley Fool

Topics Economy

ADMA BIOLOGICS INC (NASDAQ:ADMA) - A Strong Growth Candidate Meeting Minervini's Criteria ↗

June 13, 2025

ADMA Biologics (NASDAQ:ADMA) meets Minervini’s Trend Template with strong technicals and high-growth fundamentals, making it a candidate for momentum investors.

Via Chartmill

ADMA BIOLOGICS INC (NASDAQ:ADMA) – A Strong Growth Stock with Technical Breakout Potential ↗

June 09, 2025

ADMA Biologics (NASDAQ:ADMA) shows strong growth fundamentals and a technical breakout setup, making it a stock to watch in the biotech sector.

Via Chartmill

ADMA BIOLOGICS INC (NASDAQ:ADMA) – A High Growth Momentum Stock with Strong Technical Setup ↗

June 07, 2025

ADMA Biologics (NASDAQ:ADMA) shows strong earnings momentum and a favorable technical setup, making it a candidate for high-growth investors. The stock has outperformed peers and may present a breakout...

Via Chartmill

ADMA BIOLOGICS INC (NASDAQ:ADMA) – A Promising Affordable Growth Stock ↗

June 03, 2025

ADMA Biologics (NASDAQ:ADMA) shows strong growth, reasonable valuation, and solid financial health, making it an attractive candidate for investors seeking affordable growth stocks in the biotech...

Via Chartmill

ADMA BIOLOGICS INC (NASDAQ:ADMA) is not too expensive for the growth it is showing. ↗

May 09, 2025

Discover ADMA BIOLOGICS INC, an undervalued growth gem. NASDAQ:ADMA is shining in terms of growth metrics, and it's also displaying strong financial health and profitability, retaining an appealing...

Via Chartmill

Crude Oil Gains Over 2%; US Foods Posts Downbeat Earnings ↗

May 08, 2025

Via Benzinga

Why IBD 50's No. 2 Stock, ADMA Biologics, Just Plummeted By Double Digits ↗

May 08, 2025

The company makes immunoglobulin products using donated plasma.

Via Investor's Business Daily

Topics Earnings

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.